Europe Neuroblastoma Market and Competitive Landscape - 2017, provides comprehensive insights into Neuroblastoma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares. This study accurately estimates and forecast Neuroblastoma market size and drug sales. This research also provides insights into Neuroblastoma epidemiology and late stage pipeline.
The report is classified into nine sections - Neuroblastoma overview with definitions, symptoms, etiology, diagnosis, treatment options; Neuroblastoma pipeline insights covering late stage clinical trials pipeline; Neuroblastoma prevalence trends by countries; Neuroblastoma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries. The research scope includes EU5 countries - Germany, France, Italy, Spain, UK, Europe.
Research Scope:
Neuroblastoma pipeline: Find out the drugs in clinical trials for Neuroblastoma by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
Neuroblastoma epidemiology: Find out the prevalence of Neuroblastoma by countries - Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2025
Neuroblastoma products: Identify key products marketed and prescribed for Neuroblastoma by brand name, by molecule, by company, by branded / generic, by countries - Europe, Germany, France, Italy, Spain, UK, Japan
Neuroblastoma market size: Find out the market size for Neuroblastoma drugs by countries - Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2012
Neuroblastoma drug sales: Find out the sales of Neuroblastoma drugs by countries - Europe, Germany, France, Italy, Spain, UK
Neuroblastoma drugs sales forecast: Sales forecast for Neuroblastoma drugs to 2021 by countries - Europe, Germany, France, Italy, Spain, UK, Japan
Neuroblastoma market share analysis: Find out the market shares of Neuroblastoma drugs and outlook by countries - Europe, Germany, France, Italy, Spain, UK, Japan
Benefits of this Research:
Evaluate commercial market opportunities for Neuroblastoma drugs
Synthesize insights for business development & licensing
Track market size, competitor drug sales, market shares in Neuroblastoma market
Develop in-depth knowledge of competition and markets
Analyze sales data to update your brand planning trackers
Develop tactics and strategies to take advantage of opportunities in the market
Track market trends and analyze key events in Neuroblastoma market
Develop forecast models, healthcare frameworks, or economic models
Answer key business questions; supports decision making in R&D to long term marketing strategies
Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities...
The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...
SK chemicals (CEO Ahn Jae-hyun), Dongsung Chemical (Co-CEOs Baek Jin-woo and Lee Man-woo), and BYN Black Yak (Chairman Kang Tae-sun, hereinafter Black Yak) announced on the 18th that they've developed sustainable footwear materials using the...
First quarter
Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...